303 reports of this reaction
1.6% of all SIPONIMOD reports
#19 most reported adverse reaction
MEMORY IMPAIRMENT is the #19 most commonly reported adverse reaction for SIPONIMOD, manufactured by Novartis Pharmaceuticals Corporation. There are 303 FDA adverse event reports linking SIPONIMOD to MEMORY IMPAIRMENT. This represents approximately 1.6% of all 19,111 adverse event reports for this drug.
Patients taking SIPONIMOD who experience memory impairment should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MEMORY IMPAIRMENT is a less commonly reported adverse event for SIPONIMOD, but still significant enough to appear in the safety profile.
In addition to memory impairment, the following adverse reactions have been reported for SIPONIMOD:
The following drugs have also been linked to memory impairment in FDA adverse event reports:
MEMORY IMPAIRMENT has been reported as an adverse event in 303 FDA reports for SIPONIMOD. This does not prove causation, but indicates an association observed in post-market surveillance data.
MEMORY IMPAIRMENT accounts for approximately 1.6% of all adverse event reports for SIPONIMOD, making it a notable side effect.
If you experience memory impairment while taking SIPONIMOD, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.